[
    {
        "year": 2010,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Bile acids for liver-transplanted patients": {
                    "explanation": "This paper is a review paper that assesses the beneficial and harmful effects of bile acids for liver-transplanted patients. Although it mentions bile acids, which are related to the source paper's topic of tauroursodeoxycholic acid, it does not build upon or use the source paper's findings as a sub-hypothesis. Instead, it provides a general overview of the literature on bile acids in liver-transplanted patients.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2010,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Bile acids for liver-transplanted patients": {
                    "explanation": "This paper is a review paper that summarizes existing literature on the use of bile acids for liver-transplanted patients, including tauroursodeoxycholic acid. It does not present a novel hypothesis or findings that build upon the source paper.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2016,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Endoplasmic Reticulum Stress Is Implicated in Intestinal Failure-Associated Liver Disease": {
                    "explanation": "This paper has no connection to the source paper as it explores a different topic of endoplasmic reticulum stress in intestinal failure-associated liver disease, which is unrelated to the use of tauroursodeoxycholic acid after liver transplantation.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2016,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Endoplasmic Reticulum Stress Is Implicated in Intestinal Failure-Associated Liver Disease.": {
                    "explanation": "This paper has no connection to the source paper. The source paper discusses the use of tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation, whereas this paper investigates the role of endoplasmic reticulum stress in intestinal failure-associated liver disease.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2017,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Increased monocyte\u2010derived reactive oxygen species in type 2 diabetes: role of endoplasmic reticulum stress": {
                    "explanation": "This paper has no connection with the source paper, as it investigates the mechanisms of oxidative stress in type 2 diabetes, which is unrelated to the topic of tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2017,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Increased monocyte\u2010derived reactive oxygen species in type 2 diabetes: role of endoplasmic reticulum stress": {
                    "explanation": "This paper has no connection to the source paper. The source paper investigates the clinical usefulness of tauroursodeoxycholic acid after liver transplantation, while this paper explores the mechanisms of increased oxidative stress in monocytes in type 2 diabetes.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2018,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease": {
                    "explanation": "This paper has no connection to the source paper, as it focuses on inflammatory bowel disease, intestinal epithelial cell cultures, and ER stress, whereas the source paper investigates tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation. The topics are unrelated, and there is no indication that the hypothesis or findings of the source paper inspired or influenced this paper.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2018,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease": {
                    "explanation": "This paper has no connection with the source paper, as it focuses on inflammatory bowel disease and does not mention liver transplantation or tauroursodeoxycholic acid.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2019,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells": {
                    "explanation": "This paper has no connection to the source paper. The source paper investigates the use of tauroursodeoxycholic acid after liver transplantation, while this paper explores the role of progerin in atherosclerosis. The topics and research areas are unrelated.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2019,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells": {
                    "explanation": "This paper has no connection to the source paper. The source paper is about the clinical usefulness of tauroursodeoxycholic acid after liver transplantation, while this paper is about the molecular mechanism underlying progerin-driven vascular smooth muscle cell loss and its impact on atherosclerosis.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2023,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Implementation of Blockchain Technology Could Increase Equity and Transparency in Organ Transplantation: A Narrative Review of an Emergent Tool": {
                    "explanation": "This paper has no connection with the source paper as it is a narrative review discussing the application of blockchain technology in organ transplantation, which is unrelated to the topic of tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    },
    {
        "year": 2023,
        "source_paper": {
            "paperId": "4fd906ed9611b97d4247083968c0b1e02596d0da",
            "pmid": "10575563",
            "title": "One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.",
            "abstract": "BACKGROUND\nThe usefulness of ursodeoxycholic acid after liver transplantation is controversial. Tauroursodeoxycholic acid, the natural taurine-amidate, is a highly hydrophilic and cytoprotective bile salt currently under investigation.\n\n\nAIMS\nTo investigate the clinical usefulness of tauroursodeoxycholic acid after liver transplantation.\n\n\nPATIENTS\nThirty-three patients undergoing liver transplantation entered the study.\n\n\nMETHODS\nSixteen patients were randomized to receive tauroursodeoxycholic acid (250 b.i.d. for 12 months) and 17 served as controls. Tauroursodeoxycholic acid was given from day 5 after transplantation for one year.\n\n\nRESULTS\nTauroursodeoxycholic acid treatment was safe and well tolerated. No drop outs occurred. Among the 29 patients undergoing long-term follow-up, five deaths occurred (3 of whom in the tauroursodeoxycholic acid group), none of which was related to treatment. The one-year actuarial survival was 78.6% in patients treated with tauroursodeoxycholic acid and 86.7% in controls (n.s.). No differences were observed with respect to early or late graft function and survival, nor to acute cellular rejection. Tauroursodeoxycholic acid therapy was associated with lower serum cholesterol levels (p < 0.02) during the early postoperative months; with milder cholestasis; with a drop in biliary cholates but no changes in endogenous hydrophobic bile salts.\n\n\nCONCLUSIONS\nLong-term treatment with low dose tauroursodeoxycholic acid after liver transplantation is safe but does not affect graft function and survival.",
            "year": 1999,
            "citation_count": 13
        },
        "llama_output": {
            "paper_list": {
                "1. Implementation of Blockchain Technology Could Increase Equity and Transparency in Organ Transplantation: A Narrative Review of an Emergent Tool": {
                    "explanation": "This paper is a review paper and has no direct connection to the source paper, which investigates the clinical usefulness of tauroursodeoxycholic acid after liver transplantation. The review paper discusses the potential application of blockchain technology in organ transplantation, which is a different topic.",
                    "relevance": 0
                }
            },
            "top3_relevant_papers": {}
        },
        "seed": 42
    }
]